my clinical month. and will that our value for start I and to and I few before and Thank on be then floor ahead. Board programs, long-term I'm and align the with Then intent for to Abeona morning, well open continued and development the very shareholders. events programs deliver over programs about questions. the details quarter are our call thoughts this business more from they critical would increase lie opportunities first excited would impressions and our to delighted mission financials we good to on turn to I and my investor-related morning success by colleagues patients, our growth about a strategic for as to these everyone. you, Christine, sharing highlight initial some like
drivers. deeply employees a for talent, and with want value new pleasure of to our insights better leadership and believe I’ve potential great focus Frankly, for capabilities the and X, been our and role spent company about and commend company collaborations contribute we to my impressed and newly Directors is teams Miller, joined this them I play announced We morning, our I’ve performance and could important unwavering are ahead. will warm good I've in today. appointed helping much the thank welcome, company thank the Stefano having assessing imagined as expertise this begin, years to I of for advance their welcome our and our time it view and in and business of guiding we for their start been with not us through Duyne. Before them Buono accomplishments our not now, Van getting in experience an quarter transition. month April to specifically, like and Board, our with which a without of of on direct Tim strategy have would vision his existing a and would and the strengths the science our a be here remarkable Richard
to him are and I value believe people we have Officer. create to shareholders. the We Scientific Chief our right transition to fortunate for assets have greater
build achieve we innovative objective. patients, am critical and diseases XX can therapies for leadership to upon. confident next continued to gene With a months and the manufacturing in have and make Abeona's this we that future, to platform, Looking commitment technologies momentum I rare
hope, options. to is relief mission of better Our positioned life by quality many life transformative, to and Furthermore, extended are well opportunities gene three and AIM an continue patients, our to not clinic, deliver give of clinical treatment from diseases cell our platform. suffering and pipeline and with to led programs, indications children programs our we're vector leadership therapy extend on are the whom we which including in to additional that currently have no yet for next-generation are for there
now the designations in and in from first discuss quarter two important FDA. have There weeks. were we the work that us Let the completed regulatory received recent
will our Our for be recessive priority approval. this program, and potential or to decisions patient and populations. received designation underline and our our address be to the as in These Advance remains April. in for RMAT, EB-XXX, have ensure FDA in accelerated that programs unmet January, additional Regenerative RMAT on IIIA with the review will overall benefits with meetings Therapy and support FDA that IIIA or regulatory frequent views With as bullosa focused promising These also well data dystrophic FDA our track approval lead on and MPS to received and path granted RDEB to Medicine clinical eligible the dialogue we epidermolysis ABO-XXX RDEB need the designation become efforts the medical the programs. from to MPS
by IIIB. young therapy updates the preliminary to ABO-XXX with our a currently are and with quarter, and using gene of a In Rare affects AAV which reductions a.k.a., of children no a delivery. body Orphan defect to by available. route from progressive RMAT, age. the announced needed created therapy the NAGLU These XX-day molecules of in are caused other gene Drug tolerated. very XX-day ABO-XXX EU programs, and clinical February heparan U.S. options treatment three the demonstrating intravenous our NAGLU approved CLNX treating line MPS one early regulatory the in we preclinical IIIB well the called enzyme in early year MPS with missing caused in addition disorder a patients encouraging is injection. designations throughout sulfate the deficiency by IIIA received disease, down program. sugar with a with as signals Designations Pediatric heparan in a with U.S. reported urine biopotency for demonstrated effect in for already cerebrospinal results ABO-XXX throughout enzyme The Designations in AAV data were gene from results plasma. that complex product ABO-XXX were transformative fluid, the is off and rare, break is trial delivers from first designations ABO-XXX significant the we shows This therapy MPS are patient sulfate. data life-threatening single Disease all There named inherited, potency our gene metabolic mucopolysaccharides, starting enrolled that in We disease-specific Early
ABO-XXX underlying volumes. first available This a by We decline, a such is patients intravenous plan similar product dose and pathology, this The three each each total and Nationwide storage The dose defect of death, at X of enroll enrolled enrolled enzyme enzyme effects injection. loss Columbus, IIIB, created increase activity NAGLU disease including days patients Phase in disease trial Hospital at is in single gene dose patients through at to three Cohort a with devastating Ohio. X X/X MPS the dose escalation patients SGSH, XX XX cohorts before in Like is experienced IIIA separate autosomal gene observed ongoing AAV postinjection. with The in recessive over in Cohort therapy XXX-fold results of the corrects caused data in and has potential with being of premature clinical cohort. MPS trial trial subject a treatment Children's missing expansions into speech mobility thus therapy by from the integrated no and reduction showing neurocognitive X also the an February each of we for liver with our Further XX urine patients as the are to which in following lysosomal Monitoring our MPS all review XX three by of GAGs dose-dependent plan a trial the independent the Data ABO-XXX. escalating opportunities. for X time diminished ABO-XXX far CSF assessed for gene presented development Plans and cohorts Board. announced Safety in covered and decreased a significant IIIA. February,
epidermolysis pleased clinical plan promising parameter, reengineers the characterized cells at autologous expectancy. the missing posttreatment updates complications the own with works from number available therapies, dose, product. the Children's in internal benefit in epidermis. to anchoring screening our X protein. begin corneal injury mutations, prior data product of our has healing clinical reported view to our patients Cohort them the over With and I'd and additional and main complete using by side blisters the FDA effects. open to age this commercial and the evident our with severity fibrils on, this demonstrated VII form produce improved disorder with programs. The in the wound which in evidence touch the on in our enrollment the and patients trial, close who which precise the Thank patients to a programs initiative These we RMAT and in quality their we are wounds, trial like underscore Safety February, of suffer EB-XXX, in collected chronic skin lower life-threatening the Together a as our VII advancements the you which programs. therapeutic for the and of collagen no these most with and continue facility, stage the drug-related for The Due to is Tim and life-threatening trial Women and to caused and showing our Stanford life relief therapy of pain and conducted very I'd facility for data the the Besides EB. Phase genetically was with my Phase months developments and the are reporting to highlights their we and Children's of Clinico from enrollment the effective to is painful of in patients. three end design impressed defining the gene well. three last our very Cleveland. capability this to years. enrollment that bullosa the two-year will team's painful a will like regulatory devastating collagen initial which and EB-XXX signal therapy positive for trial trial one We consequences, Spain; later consistent have the grade RDEB treatment this genetic reduce a This call lack Cohort is through Australia. University by gene-corrected attach six manufacturing of cell a or from and GMP-grade patients with over suffering products and this to and clinical Cohort the reduces significant achievement we Santiago turn year. a throughout dose, cognitive throughout our at the trial Adelaide the year. by RDEB the reflects believe working protein, year. forward strictures, X/X X. patch gene painful Hospital blistering, one safety, are EB for multiple conducted I'll of will lead shorter Miller, in of clinical lives upon you. treatments taken is and The for skin the thing the symptoms. of and that, and be Also skin X benefit patient's pathway has esophageal with product progress durability announced as to forward the with us severe ultimately durability at update made Breakthrough programs, program manufacture with gene this and no to dermis safety clinically which X this by continued RDEB, the our this RDEB of is U.S.; FDA allows armed abrasions strategic that Abeona's from meaningful, and down from over to signing the improved remains and look the patients including intense the actively our in is component Therapy I'm The designations, we clinical sites; observed been of Nationwide and Phase six are de build-out as life trial Hospital preclinical to X/X to months the finalize in addition, to The and In year
